The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Cholesterol and blood fats
Does it move cholesterol or triglycerides?
Lipids measured in blood, which is a laboratory result rather than an event.
53,513 people · 14 human studies · 12 compounds
- 29,087 people2 studies
HPS2-THRIVE, NCT00461630. 25,673 adults with vascular disease on statin-based therapy randomised to 2 g extended-release niacin with 40 mg laropiprant or placebo for a median of 3.9 years. LDL was 10 mg/dL lower and HDL 6 mg/dL higher on treatment. Major vascular events occurred in 13.2 percent versus 13.7 percent,...
New England Journal of Medicine, 2014 · 25,673 people
AIM-HIGH, NCT00120289. 3,414 patients with established atherosclerotic cardiovascular disease and LDL below 70 mg/dL, randomised to extended-release niacin 1500 to 2000 mg daily (n=1718) or placebo (n=1696), all on simvastatin plus ezetimibe as needed. Stopped after a mean of 3 years for lack of efficacy. Niacin...
New England Journal of Medicine, 2011 · 3,414 people
- 20,536 people1 study
20,536 UK adults aged 40 to 80 with coronary, other occlusive arterial disease or diabetes, randomised to 40 mg simvastatin daily or placebo. All-cause mortality 12.9 percent versus 14.7 percent (p equals 0.0003). Major vascular events fell 24 percent, from 25.2 percent to 19.8 percent. Benefit held even in...
Lancet, 2002 · 20,536 people
- 2,909 people1 study
2,909 participants randomised 2:1 to enlicitide 20 mg or placebo for 52 weeks. LDL cholesterol fell 57.1 percent at week 24 against a 3.0 percent rise on placebo, an adjusted between-group difference of 55.8 percentage points (p < 0.001). Non-HDL cholesterol, apolipoprotein B and lipoprotein(a) also improved. Funded...
New England Journal of Medicine, 2026 · 2,909 people
- 268 people1 study
The largest published human trial, run by GSK: 268 people with low HDL took 2.5, 5 or 10 mg or placebo for 12 weeks. HDL cholesterol rose up to 16.9%, triglycerides fell 16.9% and apoB fell 14.9%. Twelve weeks is the longest published human exposure; the rodent carcinogenicity findings that ended development were...
Arteriosclerosis, Thrombosis, and Vascular Biology, 2012 · 268 people
- 225 people2 studies1 found nothing
Double-blind, placebo-controlled RCT, 178 patients with stable coronary artery disease already taking statins, aspirin or beta-blockers, randomized to nattokinase (3,615 FU/day), red yeast rice, the combination, or placebo for 90 days: nattokinase alone significantly lowered LDL-C versus placebo but not total...
Frontiers in Nutrition, 2024 · 178 people
found nothingRCT, 47 patients with hyperlipidemia, nattokinase alone versus nattokinase plus red yeast rice versus placebo for 6 months: the nattokinase-only arm showed no significant lipid change against placebo, while the combination arm improved triglycerides, total cholesterol, LDL-C and HDL-C from month 1. Nattokinase's own...
Asia Pacific Journal of Clinical Nutrition, 2009 · 47 people
- 192 people1 study1 found nothing
found nothingThe largest and longest diabetes trial here: 192 patients, 40 or 500 mg per day for six months. CRP fell 5.6% and 15.9% versus placebo but not significantly, and there was no significant change in weight, BMI, waist, blood pressure, fasting glucose, HbA1c, insulin, C-peptide, free fatty acids, liver enzymes, uric...
Pharmacological Research, 2016 · 192 people
- 151 people1 study1 found nothing
found nothingPooled blood lipid data from four placebo-controlled randomised studies, including three of betaine totalling 151 participants. Betaine at 6 g/d for six weeks raised LDL cholesterol by 0.36 mmol/L (95 percent CI 0.25 to 0.46), triacylglycerol by 0.14 mmol/L and the total to HDL ratio by 0.23, with no effect on HDL....
PLoS Medicine, 2005 · 151 people
- 80 people1 study
80 adults with total cholesterol at or above 200 mg/dL and/or LDL at or above 100 mg/dL, in four arms for 6 to 8 weeks: pterostilbene 125 mg twice daily, 50 mg twice daily, 50 mg plus grape extract 100 mg twice daily, or placebo. LDL rose 17.1 mg/dL on pterostilbene monotherapy (p = 0.001), an effect not seen with the...
Evidence-Based Complementary and Alternative Medicine, 2014 · 80 people
- 36 people1 study
The cost side, in a different indication. 36 patients with acquired aplastic anaemia on danazol monotherapy at 10 mg per kg per day capped at 600 mg. After 6 months HDL cholesterol fell 30 percent and LDL rose 11 percent, with significant changes in left ventricular mass, ejection fraction and diastolic indices. The...
Blood Cells, Molecules and Diseases, 2025 · 36 people
- 29 people1 study1 found nothing
found nothing29 healthy Japanese adults aged 40 to 57 with normal to moderately high triglycerides, 20 mg a day for 12 weeks, randomised and double blind. Mean triglycerides did not change. LDL cholesterol fell marginally in the PQQ group, from 136.1 to 127.0 mg/dL, with a clearer fall in the subgroup whose baseline LDL was 140...
Journal of Nutritional Science and Vitaminology, 2015 · 29 people
- no headcount stated1 study1 found nothing
found nothing48 overweight or obese non-smokers aged 20 to 65 with features of metabolic syndrome, 25 mg (-)-epicatechin a day for 2 weeks in crossover. No significant effect on blood pressure, glucose, insulin, HOMA-IR, triglycerides, total, LDL or HDL cholesterol, or oxidised LDL. The authors conclude the cocoa effect cannot be...
American Journal of Clinical Nutrition, 2018 · no headcount in the line
- no headcount stated1 study1 found nothing
found nothingRandomised 2:1, 30 overweight or obese adults aged 45 and over, MIB-626 two 500 mg tablets twice daily for 28 days. Body weight fell 1.9 kg (95 percent CI -3.3 to -0.5, P=.008), diastolic blood pressure fell 7.01 mmHg (-13.44 to -0.59, P=.034), total cholesterol fell 26.89 mg/dL (P=.004) and LDL fell 18.73 mg/dL...
Journal of Clinical Endocrinology and Metabolism, 2023 · no headcount in the line
- no headcount stated0 studies
Interventions Testing Program, three test sites, treatment beginning at 4 months of age. None of the five agents, medium-chain triglyceride oil included, had a statistically significant effect on lifespan of male or female mice by log-rank test at the concentrations tested.
Journals of Gerontology Series A, 2013 · no headcount in the line
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
- no headcount stated0 studies
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.